Tyler J. Friedrich

Tyler J. Friedrich

Oncology | Hematology

1500 Park Central Drive
Suite 101
Highlands Ranch, CO 80129

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Concurrent Ocular and Dermatologic Toxicities Associated With Docetaxel Chemotherapy.

Concurrent Ocular and Dermatologic Toxicities Associated With Docetaxel Chemotherapy.

Journal: Journal of the advanced practitioner in oncology

Published: August 01, 2026

Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer.

Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer.

Journal: JCO oncology practice

Published: July 24, 2024

A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer.

A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 14, 2024

Rectal Cancer: Clinical and Molecular Predictors of a Complete Response to Total Neoadjuvant Therapy.

Rectal Cancer: Clinical and Molecular Predictors of a Complete Response to Total Neoadjuvant Therapy.

Journal: Diseases of the colon and rectum

Published: January 05, 2022

Beyond RAS and BRAF: a target rich disease that is ripe for picking.

Beyond RAS and BRAF: a target rich disease that is ripe for picking.

Journal: Journal of gastrointestinal oncology

Published: October 18, 2016

Showing 1-5 of 5

Last Updated: 09/26/2026